Celldex Therapeutics (CLDX) Stock Forecast & Price Target

Celldex Therapeutics is supported by barzolvolimab’s differentiated mast-cell-depleting mechanism and Phase 3 EMBARQ-CSU data that met all primary and key secondary endpoints, with Week 12 complete response rates of 42%–46% and deeper responses by Week 24. Physicians in the survey viewed the drug as somewhat or much more effective, and 96% would still prescribe it in some capacity despite anaphylaxis concerns, indicating safety issues are manageable rather than prohibitive. The company also has multiple catalysts ahead, including a 24-week dataset at AAAAI in February 2027, a BLA later that year, and ongoing expansion into CIndU, atopic dermatitis, cold urticaria, and symptomatic dermographism.

Celldex Therapeutics is viewed negatively because its valuation depends heavily on barzolvolimab, a single clinical-stage asset, making the stock highly exposed to any setback in efficacy, safety, or trial execution. The company also faces meaningful clinical and regulatory risk in chronic spontaneous urticaria, chronic inducible urticaria, and atopic dermatitis, where patient recruitment could slow timelines and push results and approval farther out than expected. Competitive pressure is another major concern, as numerous approved therapies and late-stage programs could limit differentiation and adoption, while commercial execution risk may further constrain market penetration if clinicians remain anchored to existing treatments.